

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Hepatology*

**Manuscript NO:** 80297

**Title:** Adherence to guideline-directed hepatocellular carcinoma screening: A single-center US experience

**Provenance and peer review:** Unsolicited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05752753

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** India

**Author's Country/Territory:** United States

**Manuscript submission date:** 2022-11-11

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-11-21 07:31

**Reviewer performed review:** 2022-11-29 07:11

**Review time:** 7 Days and 23 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="radio"/> ] Anonymous [ <input type="radio"/> ] Onymous
	Conflicts-of-Interest: [ <input type="radio"/> ] Yes [ <input checked="" type="radio"/> ] No

## **SPECIFIC COMMENTS TO AUTHORS**

Congratulations to authors for the study and bringing forth the lacunae in screening cirrhotic patients for HCC 1. The authors have rightly pointed out that the reasons for low adherence to screening guidelines are largely institutional and partly patient related. 2. I request the authors to briefly describe the screening methods ( eg - USG , is it contrast USG? for the benefit of the readers) 3. The contrast between developed and the underdeveloped world with regards to screening guidelines , availability of imaging resources, cost vs benefit can also be briefly highlighted in the discussion. This would be of interest to the clinicians and researchers globally. 4. As pointed out primary driver of inadequate screening was radiology scheduling, the authors can review a few studies which would suggest a more pragmatic screening guidelines which would be applicable to a larger population around the world.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Hepatology*

**Manuscript NO:** 80297

**Title:** Adherence to guideline-directed hepatocellular carcinoma screening: A single-center US experience

**Provenance and peer review:** Unsolicited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05113429

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** United States

**Manuscript submission date:** 2022-11-11

**Reviewer chosen by:** Dong-Mei Wang

**Reviewer accepted review:** 2022-12-31 09:41

**Reviewer performed review:** 2023-01-02 07:04

**Review time:** 1 Day and 21 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation

<b>Scientific significance of the conclusion in this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

#### SPECIFIC COMMENTS TO AUTHORS

Hepatocellular carcinoma screening is important for patients with cirrhosis. William King et al provided a well structured paper. But The content of this paper is too simple, especially for the part of result. I suggested that the author conduct an in-depth analysis of the data and give us more attractive results.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Hepatology*

**Manuscript NO:** 80297

**Title:** Adherence to guideline-directed hepatocellular carcinoma screening: A single-center US experience

**Provenance and peer review:** Unsolicited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 02860814

**Position:** Peer Reviewer

**Academic degree:** MD, PhD

**Professional title:** Assistant Professor

**Reviewer's Country/Territory:** Greece

**Author's Country/Territory:** United States

**Manuscript submission date:** 2022-11-11

**Reviewer chosen by:** Dong-Mei Wang

**Reviewer accepted review:** 2022-12-30 09:59

**Reviewer performed review:** 2023-01-02 20:20

**Review time:** 3 Days and 10 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation

<b>Scientific significance of the conclusion in this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS

I read with great interest the paper by King et al, entitled "Adherence to guideline-directed hepatocellular carcinoma screening: A single-center US experience". The authors studied if the cirrhotic patient followed in a subspecialty hepatology clinic underwent the appropriate surveillance for HCC according to the AASLD guidelines. They included a really large cohort of patients (n = 1034) and identified that less than half of them (47%) underwent appropriate screening. Of note, screening failure was attributed to "hospital" factors and not "patient" errors. There are some parts that need clarification: - Why did the authors select the period from 2015–2017? It would be more interesting to see more recent data collected and to investigate differences between the pre- and post-covid periods. - Besides, it would be interesting to see if the delay in HCC screening affected the HCC stage at the time of diagnosis. - Were there any differences in screening delays observed that could be attributed to specific physicians? - One of the main reasons for screening failure was "radiology scheduling failure". Was this screening performed in the Radiology Department of the Hospital or in the private sector?